newsfilter
← Latest News
PR Newswire·

The9 Investee Nanyang Biologics (NYB) Advancing Planned Nasdaq Listing for the US$1.5 Billion Business Combination

  • Nanyang Biologics (NYB) obtained a notice of effectiveness from the U.S. SEC for its Form F-4 registration statement related to a planned business combination.
  • The9 Limited expects its wholly-owned subsidiary Gamenow to hold a 15% to 16% stake in the combined company following the NYB Nasdaq listing.
  • The business combination assigns NYB a pre-transaction valuation of approximately $1.5 billion.
  • The Nasdaq listing under the ticker "NYB" is subject to an SPAC shareholder vote on August 19, 2026, & final Nasdaq approval.
  • NYB is a Singapore-based AI-first drug discovery company utilizing a library of over one million natural compounds & its DTIGN neural network.
  • In August 2025, NYB signed an MoU with NVIDIA, Hewlett Packard Enterprise, & Equinix to build the world's largest natural compound library & scalable AI platforms.
  • The9 Limited is a global diversified high-tech company with a focus on AI gaming & equity stakes in AI-driven drug discovery ventures.